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Increase in α-tubulin modifications 
in the neuronal processes of 
hippocampal neurons in both kainic 
acid-induced epileptic seizure and 
Alzheimer’s disease
Hang Thi Vu1, Hiroyasu Akatsu2,3, Yoshio Hashizume2, Mitsutoshi Setou1,4,5,6,7 & Koji Ikegami1
Neurodegeneration includes acute changes and slow-developing alterations, both of which partly 
involve common cellular machinery. During neurodegeneration, neuronal processes are impaired 
along with dysregulated post-translational modifications (PTMs) of cytoskeletal proteins. In 
neuronal processes, tubulin undergoes unique PTMs including a branched form of modification called 
glutamylation and loss of the C-terminal tyrosine residue and the penultimate glutamic acid residue 
forming Δ2-tubulin. Here, we investigated the state of two PTMs, glutamylation and Δ2 form, in 
both acute and slow-developing neurodegenerations, using a newly generated monoclonal antibody, 
DTE41, which had 2-fold higher affinity to glutamylated Δ2-tubulin, than to unmodified Δ2-tubulin. 
DTE41 recognised glutamylated Δ2-tubulin preferentially in immunostaining than in enzyme-linked 
immunosorbent assay and immunoblotting. In normal mouse brain, DTE41 stained molecular layer 
of the cerebellum as well as synapse-rich regions in pyramidal neurons of the cerebral cortex. In kainic 
acid-induced epileptic seizure, DTE41-labelled signals were increased in the hippocampal CA3 region, 
especially in the stratum lucidum. In the hippocampi of post-mortem patients with Alzheimer’s disease, 
intensities of DTE41 staining were increased in mossy fibres in the CA3 region as well as in apical 
dendrites of the pyramidal neurons. Our findings indicate that glutamylation on Δ2-tubulin is increased 
in both acute and slow-developing neurodegeneration.
Neurodegeneration includes a wide range of phenomena from acute changes to slow-developing alterations. An 
example of acute events is epileptic seizures, where neurons are damaged by excitotoxicity1. Slow-developing 
events include late-onset neurodegenerative diseases, such as Alzheimer’s disease (AD), in which neurons are 
gradually lost2. Despite the huge difference in the time span of neurodegeneration, both acute and slow-developing 
neurodegenerative pathways contain common cellular machinery and molecules. Several studies have revealed 
that dysregulated protein post-translational modifications (PTMs), including cytoskeletal proteins, are involved 
in neurodegeneration. In AD, a microtubule-associated protein, tau is hyperphosphorylated, which forms neu-
rotoxic neurofibrillary tangles3. Currently believed mechanisms for tau aggregation involve self-aggregation of 
hyperphosphorylated tau and prion-like propagation of sequestering normal tau into the aggregates4. The aggre-
gated tau is thought to be linked to impairments of neuronal function in AD by affecting microtubules stability 
and function as a ‘railway’ for neuronal transports5. Aberrant phosphorylation of neurofilaments is detected in 
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a broad range of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), AD, and Parkinson’s 
disease (PD)6. Dysregulation of SUMOylation is also reported in AD human brain and mouse AD model7.
Neurons have long and thin processes called neurites, or axons and dendrites. Neuronal processes are rich in 
microtubules composed of the building block, tubulin. In neurons, tubulin is subjected to a variety of PTMs in the 
C-terminal region, such as glutamylation8, detyrosination9,10, and conversion to untyrosinatable Δ 2-tubulin11,12 
and Δ 3-tubulin13. Glutamylation is a highly unique form of PTM that generates a polyglutamate branch on a 
glutamic acid residue in the C-terminal region of tubulin8. The vast majority of neuronal tubulin undergoes 
glutamylation14. Tubulin glutamylation is, thus, important for maintaining neuronal function; for example, glu-
tamylation of α -tubulin is essential for the KIF1-mediated transport of synaptic vesicle precursors to axonal 
terminals15.
Glutamylation is catalysed by a subfamily of the tubulin tyrosine ligase (TTL)-like (TTLL) protein family16–18. 
TTLL proteins possess a conserved core catalytic domain, TTL domain16. Eight TTLL proteins, TTLL1, 4, 5, 6, 7, 
9, 11, and 13 are involved in tubulin glutamylation16–19. TTLL4 and 5 catalyse the first step, i.e., the initiation of 
glutamylation, with preferences to α - and β -tubulin, respectively18. TTLL5 also elongates the glutamate chain, i.e. 
“poly”-glutamylation, on α -tubulin18. TTLL6, 11, and 13 are involved in elongation of the glutamate chain on 
α -tubulin18. TTLL7 has a highly selective activity of both initiation and elongation on β -tubulin18,20. In neurons, 
α -tubulin polyglutamylation is mainly performed by TTLL121, and β -tubulin polyglutamylation is catalysed by 
TTLL717. Glutamylation is also reversed through deglutamylation by all members of cytosolic carboxypeptidases 
(CCPs)22,23. CCP1, 2, 3, 4, and 6 shorten polyglutamyl chains23–26. CCP5 has an additional function of removing a 
glutamate at the branching point by cutting the γ -α linkage22,23,25.
Detyrosination occurs through loss of the C-terminal tyrosine residue by unidentified carboxypeptidase(s)27, 
and detyrosinated tubulin is further converted to Δ 2-tubulin through deglutamylation of the penultimate glu-
tamic acid residue. The removal of penultimate glutamic acid residue is irreversible, resulting in the exclusion 
of Δ 2-tubulin from the reversible cycle of detyrosination/retyrosination28. About 35% of neuronal α -tubulin is 
Δ 2-tubulin28. The deglutamylation for generating Δ 2-tubulin is catalysed by the same members of CCPs as the 
reverse reaction of polyglutamylation23–26. Δ 3-tubulin is generated through the further removal of the third last 
glutamic acid residue from Δ 2-tubulin by CCP1, 4, 5, and 624,13.
Accumulating evidence also suggests that tubulin PTMs are involved in neurodegeneration. Dysregulated 
tubulin acetylation is reportedly associated with Huntington’s disease and PD29,30. Tubulin glutamylation is also 
involved in neurodegeneration. We and others have demonstrated that dysregulated over-glutamylation causes 
severe degeneration of cerebellar Purkinje cells in Ccp1-deficient mice23,24. The relative level of tubulin glutam-
ylation against tubulin amount is increased in AD brain: signal of glutamylated tubulin is specifically increased 
in apical dendrites of the CA1 pyramidal neurons remaining in AD cases while the total amount of α -tubulin is 
decreased31. In addition, toxic amyloid-β (Aβ ) transiently enhances tubulin glutamylation32.
For a better understanding of disease-related alterations in PTMs, precise and detailed analyses of PTMs 
are important. This is even more critical in the case where multiple PTMs occur on a molecule with each PTM 
located close to each other. Recently, detailed multi-phosphorylation states of tau have been analysed in AD 
brains using a new technique33. Despite long investigations on tubulin PTMs in the nervous system, few studies 
focus on the coexistence of multiple PTMs on an individual tubulin molecule in neurodegenerative conditions 
as well as in the normal brain. In this study, we generated a monoclonal antibody (mAb), DTE41 that had better 
affinities to the two modifications, glutamylation and conversion to Δ 2 form on individual α -tubulin molecules, 
which we called glutamylated Δ 2-tubulin. We found that DTE41-detected signals were increased in the stratum 
lucidum of the hippocampal CA3 region in kainic acid-administered mouse brain and in the hippocampus, espe-
cially mossy fibres of the CA3 region, in post-mortem AD brains.
Results
Characterisation of a novel monoclonal antibody, DTE41, targeting glutamylated Δ2 form of 
α-tubulin. We generated a mAb, named DTE41, to target a short peptide of C-terminal region of Δ 2-tubulin 
undergoing di-glutamylation (Fig. 1a). The primary and deduced quaternary structures of the variable region 
of mAb DTE41 showed 9 basic amino acids on the surface of the antigen-recognising domain (Supplementary 
information; Fig. S1a, S1b, and S1c). We first confirmed that mAb DTE41 detected preferentially Δ 2 form of α 
-tubulin by using recombinant tubulin tails having 3 different C-terminals, tyrosinated, detyrosinated, and Δ 2 
forms, which were fused to maltose-binding protein (MBP) (Fig. 1b). mAb DTE41 specifically recognised the Δ 2 
form of the α -tubulin tail while failing to react to tyrosinated or detyrosinated forms (Fig. 1c and S2a).
We next examined whether DTE41 reacted preferentially to the glutamylated form of Δ 2-tubulin with indi-
rect enzyme-linked immunosorbent assay (ELISA). Synthetic peptides with different numbers of glutamyl units 
from 0–4 were used for the analysis (Fig. 1d). mAb DTE41 reacted ~2-fold effectively to glutamylated Δ 2-tubulin 
than to unmodified Δ 2-tubulin (Fig. 1e). Of note, the reaction efficiency of the mAb to glutamylated Δ 2-tubulin 
was increased upon the increase in the number of glutamates in the branch (Fig. 1e). Anti-Δ 2-tubulin polyclonal 
antibody (pAb) showed no dependency of Δ 2 form recognition on glutamylation (Fig. S2a). mAb DTE41 did 
not recognise only-glutamylated tubulin, i.e. glutamylated Tyr-tubulin (Fig. S2b). Taken together, these results 
demonstrate that mAb DTE41 preferentially recognises highly glutamylated Δ 2-tubulin.
mAb DTE41 preferentially recognises glutamylated Δ2-tubulin-enriched microtubules in cul-
tured cells. We tested whether mAb DTE41 preferentially detected glutamylated Δ 2-tubulin in the cells 
expressing a glutamylating enzyme, TTLL5, and a Δ 2 form-generating enzyme, CCP1. mAb DTE41 showed the 
strongest reactivity to a 50-kDa protein in the cells co-expressing both CCP1 and TTLL5 (Fig. 2a) with a statisti-
cally significant efficiency (Fig. 2b). It also reacted weakly to a 50-kDa protein in the cells expressing only CCP1 
(Fig. 2a), though the statistical value was more than 0.05 (Fig. 2b). The conversion of α -tubulin to the Δ 2 form 
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by CCP1 expression was verified with a specific anti-Δ 2 polyclonal antibody (Fig. 2a and b). Glutamylation of 
α -tubulin by TTLL5 was also confirmed with mAb GT335, a specific mAb against glutamylated tubulin (Fig. 2a 
and b). Upper-shifting of tubulin bands detected with mAb DTE41 or anti-Δ 2-tubulin pAb were observed in 
TTLL5-overexpressing samples, while DM1A-detected tubulin bands did not show such band-shifting (Fig. 2a), 
indicating that only a part of tubulin in cells was glutamylated. A surprising result was that anti-Δ 2-tubulin pAb 
showed an increase of band intensity in cells expressing TTLL5 alone (Fig. 2a and b).
We next tested whether mAb DTE41 detected modified proteins using immunocytochemistry on COS7 cells 
co-expressing TTLL5 and CCP1. mAb DTE41 signal was detected only in cytoplasm of cells that expressed both 
TTLL5 and CCP1 (Fig. 2c; arrowhead). The antibody did not detect any signals in cells expressing either TTLL5 
or CCP1 (Fig. 2c). To evaluate the detection efficiency and selectivity of mAb DTE41 against glutamylated Δ 
2-tubulin, we quantified the DTE41-positive cells expressing TTLL5 alone, CCP1 alone, or both TTLL5 and 
CCP1. mAb DTE41 recognised about 50% of cells expressing both TTLL5 and CCP1 (Fig. 2d). In contrast, it 
detected only a few or none of the cells expressing CCP1 alone or TTLL5 alone, respectively (Fig. 2d), indicating 
that mAb DTE41 had better affinity to glutamylated Δ 2-tubulin in immunostaining compared to ELISA and 
immunoblots.
We next confirmed whether the cytoplasmic signal detected by mAb DTE41 was tubulin. The DTE41-labelled 
signals in the cytoplasm were overlapped with microtubules visualised with DM1A (Fig. 2e and f). We fur-
ther examined whether mAb DTE41-labelled structures are also co-localised with glutamylated tubulin and 
Δ 2-tubulin. The DTE41 signals were co-localised with both signals of anti-Δ 2-tubulin pAb and mAb GT335 
(Fig. 2e and f). Note that some cells labelled with anti-Δ 2-tubulin pAb were negative for mAb DTE41 staining 
(Fig. S2c), supporting the idea that mAb DTE41 detects microtubules that possess glutamylated Δ 2-tubulin pref-
erentially in immunostaining than in immunoblotting.
mAb DTE41 stained soma and dendrites of hippocampal and cortical pyramidal neurons and 
distal dendrites of cerebellar Purkinje neurons. We tested the expression level of DTE41-detected 
tubulin in the nervous system with immunoblot and immunohistochemical analyses. The immunoblot analysis 
with mAb DTE41 showed that the antibody target was highly abundant in the mouse brain lysate (Fig. 3a). Other 
organs contained none of the double-modified form, or only faint level if present, as in the testis (Fig. 3a). In con-
trast, Δ 2-tubulin was detected not only in the brain but also in many other organs including heart, stomach, small 
intestine, colon, testis, and muscle (Fig. 3a). Glutamylation was detected selectively only in the brain (Fig. 3a).
We next investigated the distribution of DTE41-detected tubulin in mouse brain by immunohistochemistry. 
DTE41-detected tubulin was detected throughout the brain (Fig. 3b). Neither non-specific binding of second-
ary anti-mouse antibodies to residual mouse immunoglobulins nor cross-reactivity of mAb DTE41 to targets 
other than glutamylated Δ 2-tubulin were detected in DTE41-stained samples (Fig. S3a and S3b). mAb DTE41 
stained the internal granule cell layer of the olfactory bulb, the frontal cortex, the molecular layer (layer I) of the 
Figure 1. Characterisation of a novel monoclonal antibody, DTE41, targeting glutamylated Δ2 form of 
α-tubulin. (a) Antigen used to generate mAb DTE41. The C-terminal part of Δ 2 form with di-glutamylation 
was used. Colour codes of the rod structure of antigen peptide are green, carbohydrate chain in Δ 2 form; 
yellow, carbohydrate chain of branched di-glutamates; blue, nitrogen; red, oxide. The peptide has in total 8 
carboxyl groups. (b) Schematic view of recombinant α -tubulin tail fused to maltose binding protein (MBP) 
with different C-terminal modifications, tyrosination (Tyr), detyrosination (deTyr), and Δ 2 form. Epitope 
of DM1A is indicated. (c) Preference of mAb DTE41 to Δ 2-tubulin. Recombinant α -tubulin C-termini with 
different modifications were subjected to immunoblotting. Original full-length blot images were provided in 
Supplementary Figure 6a. (d) Schematic view of peptides used for ELISA. (e) ELISA of mAb DTE41 against 
peptides shown in panel d.
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cerebral cortex, the thalamus, and the molecular layer of the cerebellum (Fig. 3b). Of interest, mAb DTE41 sig-
nal was absent in axon-rich regions, such as the anterior commissure, the fornix, the thalamic stria medullaris, 
the white matter of cerebellum, and neural tracts of the medulla oblongata, except for the corpus callosum and 
the ventral hippocampal commissure (Fig. 3b). The DTE41-detected substrates were almost overlapped with 
Δ 2-tubulin, with minor differences such as stronger mAb DTE41 signals in the corpus callosum (Fig. S4a). We 
further analysed in more detail three different regions of the mouse brain, cerebral cortex, cerebellar cortex, and 
hippocampus.
Figure 2. mAb DTE41 preferentially recognises microtubule enriched by the glutamylated Δ2 form in 
cultured cells. (a) Representative western blot analyses with 3 different antibodies in HEK293T cells. Original 
full-length blot images were provided in Supplementary Figure 6b. (b) Quantitative analyses of western blotting 
as shown in panel a. Results are shown as the mean of four independent experiments. Error bars represent 
S.E.M. (c) Immunocytochemical analyses of mAb DTE41 in COS7 cells. mAb DTE41 was reactive only to 
cells expressing both TTLL5 and CCP1 (arrowhead). Scale bar, 20 μ m. Green, EGFP-TTLL5; red, DTE41; 
blue, CCP1-flag. (d) Quantification of mAb DTE41-positive cells in panel c. (e,f) Co-labelling of modified 
microtubule with mAb DTE41, mAb GT335, and anti-Δ 2-tubulin pAb. COS7 cells or IMCD3 cells co-
expressing TTLL5 and CCP1 were labelled with mAb DTE41 and mAb DM1A, mAb GT335, or anti-Δ 2- 
tubulin pAb. Red, DTE41; green, DM1A (upper), Δ 2-tubulin (middle), or GT335 (bottom); blue, DAPI. Panel f 
shows magnified images in a box of dashed line in panel e. Scale bar, 10 μ m.
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In the cerebral cortex, DTE41-detected signals were predominantly localised in the periphery of cell bodies of 
pyramidal neurons (Fig. 3c, left, arrowhead), whereas limited colocalisation was observed with MAP2-positive 
dendrites. Highly-magnified photomicrographs showed that mAb DTE41 stained granular substrates in the 
Figure 3. mAb DTE41-labelled mouse brain neurons showed a similar staining pattern to that of anti-
Δ2-tubulin pAb and different from mAb GT335. (a) Representative western blot analyses of mouse tissue 
extracts with mAb DTE41, mAb GT335, and anti-Δ 2-tubulin pAb. Original full-length blot images of GT335, 
anti-Δ-2-tubulin pAb, and mAb DM1A were provided in Supplementary Figure 6c. (b) Immunohistochemical 
staining of whole mouse brain section with mAb DTE41 and MAP2. Arrowheads: corpus callosum, and 
ventral hippocampal commissure. Arrows: the anterior commissure, fornix, and thalamic stria medullaris. 
Asterisk, white matter of the cerebellum. Green, DTE41; red, MAP2; blue, nuclei. Scale bar, 2 mm. (c,d) 
Immunohistochemical staining of tissue sections of the cerebral cortex (c) and cerebellum (d) with mAb 
DTE41, mAb GT335, and anti-Δ 2-tubulin pAb. Arrowhead, cell body; arrow, dendrite; asterisk, substrate of 
molecular layer of the cerebellum; check mark, climbing fibre. Green, modified tubulins; red, MAP2; blue, 
nuclei. Scale bar, 40 μ m. (e,f) Magnified images of DTE41 staining on the cerebral cortex (e) and cerebellum (f). 
Scale bar, 30 μ m. Green, DTE41; red, MAP2; blue, nuclei.
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cerebral cortex (Fig. 3e), indicating that they were localised in regions close to the synapse. DTE41 signals were 
also strongly detected on the surface of the cell body (Fig. 3e, arrowhead). MAP2-positive structures were infre-
quently detected by mAb DTE41 (Fig. 3e, arrow). The distribution of DTE41-detected signals in the cerebral 
cortex was highly similar to that of the Δ 2-tubulin, which was also abundant in the periphery of cell bodies and 
negative in MAP2-positive dendrites (Fig. 3c, middle). Double staining with mAb DTE41 and anti-Δ 2-tubulin 
pAb further demonstrated that signals detected with the two antibodies were almost overlapped (Fig. S4b). These 
results were in contrast to the distribution of GT335-detected glutamylated tubulin, which overlapped with 
MAP2-postive dendrites (Fig. 3c, right, arrow).
In the cerebellum, DTE41-detected signals were most strongly detected in the molecular layer (Fig. 3d, left, 
asterisks), localising in spots in the MAP2-positive main dendritic shaft of Purkinje neurons (Fig. 3d, left, arrow). 
In addition, DTE41-detected signals were detected in thin climbing fibres around soma and dendrites of Purkinje 
neurons (Fig. 3d, left, check marks). The cell bodies of Purkinje neurons were only weakly stained by mAb DTE41 
(Fig. 3d, left). Highly-magnified photomicrographs showed that mAb DTE41 stained granular substrates in the 
molecular layer (Fig. 3f), indicating that they were localised close to synapses. Figure 3f also shows that DTE41 
signals were detected in a portion of MAP2-positive main dendritic shafts of Purkinje neurons (Fig. 3f, arrow), 
and thin climbing fibres (Fig. 3f, check mark). Δ 2-tubulin was also detected in the molecular layer (Fig. 3e, 
middle, asterisks), but absent in MAP2-positive dendrites of Purkinje neurons (Fig. 3e, middle). Similar to 
DTE41-detected signals, Δ 2-tubulin was also detected in climbing fibres (Fig. 3e, middle, check mark) but not 
in the cell bodies of Purkinje neurons (Fig. 3e, middle). Similar staining patterns of mAb DTE41 and anti-Δ 
2-tubulin pAb were also observed in double staining (Fig. S4c). Glutamylated tubulin was highly abundant in the 
cell bodies and MAP2-positive main shaft of dendrites of Purkinje neurons (Fig. 3d, right, arrow and arrowhead).
In the hippocampus, DTE41-labelled signals were detected in the cell bodies of pyramidal neurons (Fig. S4d, 
left), and also present as puncta in the regions of apical dendrites of pyramidal neurons (Fig. S4d, left). Double 
staining with mAb DTE41 and anti-Δ 2-tubulin pAb showed that signals detected with the two antibodies were 
mostly overlapping (Fig. S4d).
DTE41-detected tubulin is increased in the stratum lucidum of the hippocampal CA3 region 
under acute kainate-induced epileptic seizure. We examined whether the level of DTE41-detected 
tubulin was altered during an acute phase of neuronal degeneration. To this end, we analysed the modifica-
tion level by DTE41 immunoblotting in the hippocampi of kainate-induced epileptic seizure mouse model. The 
DTE41-detected signal was significantly increased in the kainate-treated hippocampus compared to untreated 
controls (Fig. 4a and b). In contrast, the glutamylation and Δ 2-tubulin signal were not changed (Fig. 4a and b).
We next confirmed the increase in DTE41-detected signals in the hippocampus through immunohisto-
chemical staining. We focused on the hippocampal CA3 region since the region was most affected by kainate 
administration. DTE41-detected tubulin was increased in the hippocampal CA3 region by kainate administration 
(Fig. 4c, left), particularly in the stratum lucidum (Fig. 4d, left). In contrast, Δ 2-tubulin and glutamylated tubulin 
appeared to be unaltered or barely increased in the CA3 region and the stratum lucidum (Fig. 4c and d). The mAb 
DTE41-labelled signals were not non-specific detections of leaked or residual immunoglobulins (Fig. S5a). The 
increase in DTE41 signals in the stratum lucidum of the CA3 regions was reproduced in kainate-administrated 
rats (Fig. S5b and S5c). Higher magnification demonstrated that signals detected with mAb DTE41 were localised 
on mossy fibres, which were positive for calbindin (Fig. 4e). In particular, DTE41 signals were strongest at the 
periphery of calbindin signals, indicating that the targets of mAb DTE41 were localised near synapses in mossy 
fibres (Fig. 4e).
Quantitative analyses of immunofluorescence intensities in the CA3 region showed that DTE41-detected sig-
nals were significantly increased by 2.5-fold compared to the control in the kainate-administered hippocampal 
CA3 region (Fig. 4f). The level of Δ 2-tubulin showed a slight tendency of increase after the kainate adminis-
tration; however, there was no statistical significance (Fig. 4f). The change of glutamylated tubulin level was 
not statistically significant in the kainate-administered versus the control CA3 region (Fig. 4f). The levels of 
two enzymes, TTLL1 and CCP1, which are predominantly involved in regulation of tubulin glutamylation and 
Δ 2-tubulin formation in the brain, were not changed in the kainate-treated hippocampus (Fig. 4g and h). Our 
data demonstrated that DTE41-detected tubulin was increased in the acute phase of neurodegeneration.
DTE41-detected tubulin is increased in the apical dendrites of pyramidal neurons and mossy 
fibres of the CA3 hippocampal region in Alzheimer’s disease (AD). Next, we examined whether 
DTE41-detected tubulin was altered in a slow-developing neurodegenerative disease, AD, by immunostaining 
post-mortem brain specimens. We analysed the hippocampus of 8 AD brain samples and 9 non-AD brain sam-
ples (Table 1). In all the CA1, CA2, and CA3 regions of AD hippocampus, DTE41-detected signals were sig-
nificantly increased (Fig. 5a, right graph). In particular, the signals were prominent in apical dendrites of the 
hippocampal pyramidal neurons of AD brain (Fig. 5a, black arrows). Of note, the DTE41-detected signals were 
remarkably increased in mossy fibres of the CA3 region in AD hippocampus (Fig. 5a, red arrows). The level of Δ 
2-tubulin, in contrast, showed a slight tendency of decrease in AD hippocampi compared to non-AD controls, 
though the difference was not statistically significant (Fig. 5b, right graphs). Glutamylated tubulin was detected 
in the apical dendrites of pyramidal neurons in all the hippocampal CA1, CA2 and CA3 regions at comparable 
levels in both AD and non-AD samples (Fig. 5c), with a tendency of decrease in the CA2 region and increase in 
the CA3 region of AD samples (Fig. 5c, right graph). α -Tubulin level detected with mAb DM1A showed mar-
ginal difference between the non-AD and AD hippocampi (Fig. 5d). The level of DTE41-detected signals was 
correlated only with the Braak stage (Fig. 6a). Of interest, Fig. 6a shows that the highest signals tend to be at the 
Braak stage IV. The disease duration, age at death, and post-mortem interval were not correlated to the level of 
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Figure 4. mAb DTE41 immunoreactivity is increased in the mossy fibre-rich layer of the hippocampal 
CA3 region in kainate-induced epilepsy. (a) Representative western blots of mAb DTE41, mAb GT335, and 
Δ 2-tubulin in the hippocampus of kainate-treated mouse. Original full-length blot images were provided 
in Supplementary Figure 7a. (b) Quantitative analyses of western blotting as shown in panel a. Results are 
shown as the mean of 4 independent experiments. Error bars represent S.E.M. (c) Immunohistochemical 
staining of the hippocampal CA3 region with mAb DTE41. SL, stratum lucidum. Scale bar, 100 μ m. (d) 
Magnified photographs in the square of the panel c. Scale bar, 100 μ m. (e) Co-staining of the kainate-
administrated hippocampal CA3 region with mAb DTE41 and anti-calbindin pAb. (f) Quantitative analyses of 
immunofluorescence signal in panel d. Results are shown as the mean of 3 independent experiments. Error bars 
represent S.E.M. (g) Representative western blots of TTLL1 and CCP1 in the hippocampus of kainate-treated 
mouse. Original full-length blot images were provided in Supplementary Figure 7b. (h) Quantitative analyses 
of western blotting shown in panel g. Results are shown as the mean of 4 independent experiments. Error bars 
represent S.E.M.
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DTE41-stained signals (Fig. 6b,c and d). Our data demonstrate that DTE41-detected tubulin was increased in 
AD, a slow-developing neurodegenerative disease.
Discussion
In this study, we generated mAb DTE41 that targeted to glutamylated Δ 2-tubulin. mAb DTE41 recognised ‘naked’ 
Δ 2-tubulin as well as glutamylated Δ 2-tubulin with about two-fold higher affinity on the “double-modified” 
tubulin (Fig. 1). This result indicates that mAb DTE41 recognises primarily Δ 2-tubulin and glutamylated 
Δ 2-tubulin in addition. mAb DTE41 did not recognise glutamylated Tyr-tubulin (Fig. S2b). This double depend-
ency on a poly-glutamate branch and C-terminal states is different from the characteristic of mAb ID5: its interac-
tion to α -tubulin depends on the –EE motif, which is common for both detyrosinated form and glutamylation34. 
This double dependency is in contrast to other commonly used mAbs for glutamylated tubulin, GT335 and 
B3. Both GT335 and B3 are thought to recognise glutamylation regardless of C-terminal states35. Given that 
Δ 2-tubulin purified from bovine brain also undergoes polyglycylation36, the effects of polyglycylation on the 
recognition efficiency of DTE41 for Δ 2-tubulin are of interest for future studies.
One could argue that mAb DTE41 simply detects Δ 2-tubulin. This might be true as signals detected with mAb 
DTE41 and anti-Δ 2-tubulin pAb mostly overlapped in the whole brain section (Fig. S4). However, a possibility 
remains that mAb DTE41 detected glutamylated Δ 2-tubulin in some situations. Our data indicate that one such 
situation occurs in immunostaining. In immunocytochemistry, for instance, cells labelled with anti-Δ 2-tubulin 
pAb were not necessarily positive for mAb DTE41 (Fig. S2c). This supports the notion that DTE41 recognises the 
additional glutamylation on Δ 2-tubulin preferentially in immunostaining.
The initial evaluations of mAb DTE41 revealed two unexpected results. One is that DTE41 preferentially 
recognised the Δ 2-tubulin C-terminal parts that had longer glutamate chains than those carrying shorter chains, 
although the antibody was generated against di-glutamylated Δ 2-tubulin. This could result from the presence of 
9 basic amino acids on the surface of antigen recognition pocket of DTE41 (Fig. S1), which is incidentally equal 
to the number of glutamic acid residues on the quad-glutamylated Δ 2-tubulin C-terminal portion. It is not sur-
prising that a mAb shows different target preferences in immunoblot and immunostaining. The other unexpected 
result is that TTLL5 induced an increase in Δ 2-tubulin expression in HEK293T cells. A possible mechanism is 
that TTLL5-mediated glutamylation stabilises microtubules, which results in the Δ 2-tubulin increase37. Our data 
excluded the possibility that the anti-Δ 2-tubulin pAb used in this study recognises glutamylation on Δ 2-tubulin 
as the pAb reacted to Δ 2-tubulin independent of glutamylation. One would expect that mAb DTE41 could detect 
the possible Δ 2-tubulin generated by TTLL5 overexpression. However, mAb DTE41 failed to detect tubulin in 
TTLL5-overexpressing samples (Fig. 2b and d). One explanation might be that mAb DTE41 could not bind to 
Δ 2-tubulin tail with long poly-glutamate chains. Indeed, mAb DTE41 did not detect highly acidic α -tubulin with 
long polyglutamate chain (Fig. S2b). mAb DTE41 might have an optimal range of glutamate residues to recognise 
Δ 2-tubulin. The length of polyglutamate chain on Δ 2-tubulin might fall in the optimal range for DTE41 binding 
by the co-expression of CCP1 with TTLL5.
No Diagnosis Gender
Age at death 
(years)
Duration 
of disease 
(years)
Braak 
stage
CERAD 
score
Postmorterm 
interval (hours) Clinical diagnosis
1
AD
Female 82 12 V C 18 Alzheimer’s disease, chronic subdural hematoma, lung cancer
2 Female 90 6 IV C 6 Alzheimer’s disease, lung cancer
3 Female 82 6 VI C 6 Alzheimer’s disease
4 Female 88 16 VI C 6.5 Alzheimer’s disease
5 Female 74 18 VI C 17 Alzheimer’s disease
6 Male 93 6 IV C 3 Alzheimer’s disease, dementia with Lewy Bodies
7 Female 88 10 IV C 5
Alzheimer’s disease, senile 
dementia with neurofibrillary 
tangle
8 Male 76 1 IV C 10 Alzheimer’s disease, pneumonia, pancytopenia, kidney failure
9
non-AD
Male 72 2 I 0 12.5 Lung cancer brain metastasis
10 Female 80 12 II 0 3 Frontotemporal lobar degeneration
11 Male 98 2 I C 4.5 Dementia, pneumonia
12 Male 85 1 I A 2.5 Dementia, duodenal ulcer
13 Male 76 0.5 I 0 3.5 Cerebral infarction, pneumonia
14 Female 85 4 II B 2.5 Subarachnoid hemorrhage, acute myocardial infarction
15 Male 65 5 I 0 14 Dementia, pancreatic cancer
16 Male 83 12 I 0 14 Dementia, cerebral infarction, normal pressure hydrocephalus
17 Male 78 9 I B 3 Vascular dementia
Table 1.  Demographic data for patients with Alzheimer’s disease (AD) and non-AD subjects.
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DTE41-detected signals were abundantly detected in the neurons of mouse brain (Fig. 3). This result is 
expected since the vast majority of tubulin is glutamylated in the brain14 and about 35% of tubulin is Δ 2 form28. In 
addition, both modifications are accumulated in highly stable microtubules12,38. In fact, glutamylated Δ 2-tubulin 
is higher in the adult brain, where neuronal processes and their microtubules are more stable than that in neo-
natal brain39. It is plausible that tubulin detected with mAb DTE41 in mouse brain under the normal condi-
tions is predominantly Δ 2-tubulin since the staining pattern of mAb DTE41 largely overlapped with Δ 2-tubulin 
(Fig. S4). Another explanation, however, could be possible that Δ 2-tubulin and glutamylated Δ 2-tubulin hap-
pened to show almost identical distribution. This is likely, given that the vast majority of tubulin is glutamylated 
in the brain14, and ‘naked’ Δ 2-tubulin was hardly detected in the brain15. In the cerebellum, the distribution of 
mAb DTE41 signals was almost identical to that of Δ 2-tubulin (Fig. S4c)12. In contrast, the difference between 
mAb DTE41 and mAb GT335 staining patterns was prominent in the cerebellum, while that in the cerebral cortex 
was subtle. In the soma and the main shaft of Purkinje neurons, glutamylated tubulin detected by GT335 is likely 
to be mostly tyrosinated or detyrosinated forms. Indeed, both glutamylated tubulin and tyrosinated tubulin have 
been strongly detected in soma and the main shaft of Purkinje neurons40. In contrast, parallel fibres and climbing 
fibres have some populations of Δ 2-tubulin that seem to undergo glutamylation with glutamate chains of optimal 
length for DTE41. In particular, the granular staining of DTE41 and Δ 2-tubulin in the molecular layer of cere-
bellum and cerebral cortex suggests that Δ 2-tubulin and glutamylated Δ 2-tubulin were abundant near the axon 
terminals close to synapses.
DTE41-detected signals were increased upon acute epileptic seizure induced by kainic acid administration 
(Fig. 4). The increase of DTE41-detected signals was clear in immunohistochemistry, while being modest in west-
ern blotting. A possible reason of the difference is that tubulin extracted from CA1 and CA2 regions could dimin-
ish the increase of DTE41 signal in CA3 region. Another explanation is that DTE41 recognises the glutamylation 
on Δ 2-tubulin more preferentially in immunohistochemistry than in western blotting, as discussed above for 
the results of Fig. 2. Given that Δ 2-tubulin showed marginal increase in response to kainic acid administration, 
the increase in DTE41 signals could reflect an increase in glutamylated Δ 2-tubulin. In this scenario, Δ 2-tubulin 
might preferentially undergo glutamylation with longer glutamate chains, and/or glutamylated tubulin with 
longer glutamate chains might be converted to Δ 2-tubulin. This raises a question whether glutamylated tubu-
lin or Δ 2-tubulin undergoes another modification. Some evidence implies that both modifications are altered 
simultaneously. A key report provides evidence that tubulin glutamylation is increased by neuronal activity in the 
central nervous system41. Given that kainic acid causes hyperexcitation of neuronal cells42, enhanced neuronal 
activation could induce the increase in glutamylated Δ 2-tubulin. Enzymatic activity seems to be modulated, since 
Figure 5. mAb DTE41 immunoreactivity is increased in the hippocampus, especially in mossy fibres of 
the CA3 region in Alzheimer’s disease brain. (a) Immunohistochemical staining of Alzheimer’s disease (AD) 
brain and non-AD brain with mAb DTE41. Black arrows, apical dendrites; red arrows, mossy fibres. Graphs 
show the quantified DTE41-labled signal in each region of the hippocampus. Error bars represent S.E.M. (b–d) 
Immunohistochemical staining of AD brain and non-AD brain with mAb GT335 (b), anti-Δ 2-tubulin pAb  
(c), and mAb DM1A (d). In each data set, left are lower magnified images, and right are higher magnified 
images. Scale bars, 50 μ m in all photomicrographs. Brown pigments are signals stained with antibodies. Graphs 
show the quantified signal intensities of each antibody in each hippocampal region.
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the total amount of enzyme did not increase (Fig. 4g and h). A key molecule of kainic acid-mediated excitotoxic-
ity is calcium ion43. In vitro enzymatic activity of CCP1, a Δ 2-tubulin-generating enzyme, prefers the presence of 
calcium ion (Ca2+)24. Ca2+ increases the activity of CCP1 enzyme that leads to the increased signal of Δ 2-tubulin. 
The region where DTE41-detected signals were increased is consistent with the region where neuronal cells were 
most affected metabolically by kainic acid44. This difference suggests that tubulin in mossy fibres of the stratum 
lucidum is mainly converted to glutamylated Δ 2-tubulin. Indeed, DTE41-stained substrates were colocalised 
with the mossy fibre marker, calbindin, and most strongly detected at the edge of calbindin signals, indicating 
that the increase of DTE41 signals occurred near axonal terminals close to synapses. The presence of presynaptic 
kainate receptors in mossy fibres supports this idea45. In addition, this is in contrast to DTE41 signals that were 
primarily weak in white matters where synapses are rare.
In AD, DTE41-detected signals were increased in 3 different regions of the hippocampus, the CA1, CA2, and 
CA3 (Fig. 5). Similar to kainic acid-induced acute epileptic seizure, the increase in DTE41 signals indicates an 
increase in glutamylated Δ 2-tubulin, given that Δ 2-tubulin levels were not changed in AD hippocampus. The 
possible increase in glutamylated Δ 2-tubulin in the apical dendrites of pyramidal neurons is partially consistent 
with a previous study that showed that the relative level of glutamylated tubulin against α -tubulin is increased in 
the apical dendrites of AD brain31, although there are some differences between our results and findings shown in 
that study. In our experiments, the signal of α -tubulin (DM1A) was not significantly decreased. This might be due 
to the different antibodies used; albeit this cannot be fully argued because information about the antibody used 
in that study was not provided. Alternatively, disease stages used in that study might be later than in our samples, 
though Braak stage was not described31. Of interest, the DTE41-detected signal, i.e. possible glutamylated Δ 
Figure 6. Correlation analyses of mAb DTE41-detected signal intensities against AD Braak stage, duration 
of disease, age at death, and postmortem interval. (a–d) The levels of DTE41-labelled signals plotted against 
Braak stages (a), disease duration (b), age at death (c), and post-mortem interval (d). A Pearson’s test were 
performed to evaluate the correlations between the parameters.
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2-tubulin, was increased in mossy fibres of the CA3 region in AD samples. This raises a question about the molec-
ular mechanisms underlying the specific increase in glutamylated Δ 2-tubulin in mossy fibres. One study provides 
a clue; impaired inhibitory circuit and spontaneous seizure epilepsy are observed in a mouse model of AD46. 
This fits well with our proposed model for the similar selective increase in glutamylated Δ 2-tubulin in the mossy 
fibre-rich stratum lucidum under acute kainic acid-induced epileptic seizure. Overactivation of mossy fibres due 
to the failure of inhibitory inputs could increase glutamylation on Δ 2-tubulin up to levels that are difficult to be 
detected by mAb GT335. In fact, glutamylation is increased by the suppression of inhibitory inputs41. Calcium 
dyshomeostasis is well documented as an early event in AD47. The increase in glutamylated Δ 2-tubulin might be 
an early event in AD. This scenario fits well with our finding that the signal intensities of DTE41 were highest in 
the early stage of AD (Braak IV) (Fig. 6a). Dysregulation of α -tubulin modifications near axonal terminals and 
presynapse could affect intra-axonal trafficking at the terminal as well as synaptic structures and function5, which 
induces neuronal dysfunction and ultimately degeneration.
In conclusion, the detection pattern of our new antibody DTE41 indicates that two different PTMs, glutamyl-
ation and Δ 2 form, coexist on a single tubulin molecule, and that the double-modified tubulin, i.e. glutamylated 
Δ 2-tubulin is increased in both acute epileptic seizure and slow-developing AD. Our findings imply that the 
alteration of tubulin PTMs occur preferentially on already-modified tubulin, and indicate that the increase in 
glutamylated Δ 2-tubulin is a common event in both acute and slow-developing neurodegeneration.
Methods
Ethical standards. All the experiments analysing specimens of post-mortem human brains were performed 
according to the protocols approved by the Ethics Committee at the Hamamatsu University School of Medicine 
and the Choju Medical Institute, Fukushimura Hospital. Informed consent was obtained from all patients. Patient 
information was anonymised, and data presented in this study do not identify participants. All the experiments 
using mice were conducted according to the protocols approved by the Institutional Animal Care and Use 
Committee at the Hamamatsu University School of Medicine.
Antibodies. A mAb (clone DTE41) was generated against a branched peptide that was the C-terminal por-
tion of Δ 2-tubulin having branched di-glutamates (Kohjin Bio, Saitama, Japan). The antibody subclass was 
IgG1κ . Primary and deduced quaternary structures of DTE41 were analysed as described in supplementary 
information. The culture supernatant of the P3U1 hybridoma producing mAb DTE41 was used for the exper-
iments. The other antibodies used were anti-glutamylated tubulin mAb GT335 (AdipoGen, San Diego, CA); 
anti-tyrosinated tubulin mAb TUB-1A2, anti-α -tubulin mAb DM1A, anti-MAP2 mAb HM-2, anti-MAP2 pol-
yclonal antibody (pAb), and anti-FLAG mAb M2 (Sigma-Aldrich, St. Louis, MO); anti-detyrosinated tubulin 
pAb, anti-Δ 2-tubulin pAb, and anti-GAPDH mAb 6C5 (Millipore, Billerica, MA); anti-calbindin pAb (#ab11426; 
Abcam, Cambridge, UK); anti-TTLL1 antibody (Ikegami PNAS 2010); anti-AGTPBP1 (Proteintech, Rosemont, 
IL); AlexaFluor-conjugated secondary antibodies for immunostaining (Thermo Fisher Scientific, Waltham, MA); 
and horseradish peroxidase-conjugated secondary antibodies for immunoblotting (Jackson ImmunoResearch 
Laboratories, West Grove, PA).
AD brain and non-AD brain samples. Post-mortem hippocampus specimens were prepared from 8 
AD patients and 9 non-AD subjects in the Choju Medical Institute as previously described48. The brain was 
removed at autopsy, weighed, cut mid-sagittally, and examined for vascular and the other macroscopically detect-
able lesions. Specimens for experiments were taken from the right hemisphere, or from the unaffected hemi-
sphere as determined by computed tomography, and fixed in 4% paraformaldehyde (PFA) after dividing into 
several regions. The specimens were embedded in paraffin and processed into 5 μ m sections for histological and 
immunohistochemical examination. For diagnosis, tissue sections were stained using hematoxylin-eosin and 
Klüver-Barerra staining methods. Gallyas-Braak staining49,50 was used to detect senile plaques (SPs), cerebral 
amyloid angiopathy (CAA) and neurofibrillary tangles (NFTs). Amyloid histopathology was assessed according 
to the Consortium for Establishing a Registry for Alzheimer’s Disease (CERAD) scores51 for SPs, and Braak stag-
ing for NFTs52 were quantified as indicative of AD pathology. The serial sections of specimens were also stained 
with mAb 6E10 (BioLegend, San Diego, CA) for detecting Aβ , mAb AT8 (Fujirebio Europe, Gent, Belgium) for 
phosphorylated paired helical filament (PHF)-tau (pSer202/pThe205), mAb pSyn#64 (Wako, Osaka, Japan) for 
phosphorylated α -synuclein, and mAb 11–9 (Cosmo Bio, Tokyo, Japan) for phosphorylated TAR DNA-binding 
protein 43 kDa (TDP-43) (phosphor Ser409/410), to exclude false positive diagnosis of AD.
Kainic acid-induced epileptic seizure mouse model. Eight-week-old male mice were intraperitoneally 
injected with kainate (25 mg/kg body weight). Mice showing severe and conclusive seizure at 30 min after kainate 
injection were used. Mice injected with phosphate-buffered saline (PBS) were used as controls. Mice were fixed 
with 4% PFA through perfusion fixation at 6 h after the injection. Brains were further fixed in 4% PFA/PBS at 
4 °C overnight after dissection. The fixed brains were incubated in 10% and 20% sucrose at 4 °C for 20 h and then 
embedded in OCT compound (Sakura Finetek, Tokyo, Japan) with metal attachment at − 190 °C. The frozen 
OCT-embedded tissue blocks were sagittally sectioned at 10 μ m in thickness using a cryostat (CM 3050; Leica, 
Wetzlar, Germany) at − 20 °C. The sagittal brain sections were attached on MAS-coated glass slides (Matsunami, 
Osaka, Japan).
Recombinant proteins and synthetic peptides. A complementary DNA (cDNA) fragment corre-
sponding to amino acids 412–451 (GMEEGEFSEAREDMAALEKDYEEVGVDSVEGEGEEEGEEY) of human 
α -tubulin 1A was inserted into pMAL-c2x. To generate detyrosinated form and Δ 2 form, the last codon (TAC for 
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Tyr) or the penultimate codon (GAA for Glu) was replaced with a stop codon (TAG or TAA, respectively) using 
the Quick Change® II Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA). The sequences were 
checked with the Prism 3130 sequencer (Applied Biosystems, Waltham, MA). The maltose binding protein-fused 
α -tubulin 1A tails were expressed in an E. coli strain, BL21-CodonPlus® -RIL Competent Cells (Agilent 
Technologies) by induction with a final concentration of 0.3 mM isopropyl-γ -thiogalactopyranoside (IPTG) at 
37 °C. Harvested cells were sonicated in PBS containing a protease inhibitor cocktail (Roche, Basel, Switzerland) 
on ice using an ultrasonic processor (MicrosonTM Ultrasonic Cell Disruptor XL; Misonix, Farmingdale, NY). The 
supernatants obtained after 20000 × g centrifugation were subjected to western blotting. The C-terminal peptides 
of Δ 2-tubulin possessing different lengths of glutamates chains were purchased from Peptide, Inc. (Japan). The 
primary C-terminus of synthetic peptides was converted to –COOH, which was determined by mass spectrome-
try results provided by the manufacturer along with peptides.
Enzyme-linked immunosorbent assay (ELISA). Synthetic peptides were coupled to bovine serum albu-
min (BSA) using glutaraldehyde. BSA dissolved in glutaraldehyde without the addition of peptides was used 
as the negative control. Indirect ELISA was carried out in 96-well flat-bottom microtitre plates (F96 Maxisorp 
NUNC-Immuno plate; Thermo Fisher Scientific). The cross-linked peptides were adsorbed to the well surface 
of ELISA plate by overnight incubation at 4 °C. The wells were blocked with 10% goat serum for 2 h at room 
temperature. Serial dilutions of mAb DTE41 in 5% goat serum blocking buffer were added to the wells and 
incubated overnight at 4 °C. The primary antibody was labelled with HRP-conjugated anti-mouse IgG goat anti-
bodies (1:10000) for 2 h at room temperature. The wells were filled with 100 μ L of 3,3′ ,5,5′ -Tetramethylbenzidine 
(TMB) substrate solution. After colour development, 100 μ L of 1N hydrochloric acid was added to stop the reac-
tion, and the absorbance of 450-nm light was recorded as optical density (OD) values with a microplate reader 
(SynergyTM−HT; Bio-TEK Instruments, Winooski, VT).
Cell culture and plasmid transfection. Cells were cultured and transfected with plasmids as previously 
described53. Human embryonic kidney (HEK) 293 T cells and COS7 cells were grown in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% foetal bovine serum (FBS) at 37 °C with 5% CO2. IMCD3 cells 
were grown in DMEM/F12 medium supplemented with 10% FBS at 37 °C with 5% CO2. For plasmid transfection, 
the cells with 50–75% confluency were transfected by using LipofectamineTM 2000 (Thermo Fisher Scientific) 
or polyethylenimine (Polysciences, Inc., Warrington, PA). Transfected cells were subjected to experiments at 
24 h after transfection. The plasmids used were pCMV-TTLL5–Flag, pEGFP-TTLL5, and pCMV-CCP1-Flag. 
The empty pCMV-Tag vector was used for mock transfection. The P3U1 hybridoma was grown in RPMI medium 
supplemented with 15% FBS and Hybridoma Fusion and Cloning Supplement (Roche). To prevent depolymeri-
sation of the microtubules, the cells were treated with 1 μ M taxol for 1 h prior to fixation.
Immunoblotting. Mouse organs were homogenised in 1× sample buffer (Wako) by a Teflon homogeniser. 
HEK293T cells were lysed in a hypotonic lysis buffer (50 mM Tris, pH 7.6, 1% Triton X-100). The supernatants at 
20000 × g were used for western blotting. Protein concentration was determined by Bradford’s method. Proteins sep-
arated in SDS-PAGE were transferred to polyvinylidene fluoride membrane (PVDF; GE Healthcare, Chicago, IL), 
and reacted with specific antibodies (DTE41 at 1:200, GT335, 1:5000; DM1A, 1:5000; Tub-1A2, 1:1000; 
anti-detyrosinated tubulin pAb, 1:500; anti-Δ 2-tubulin pAb, 1:1000; M2, 1:5000; 5C6, 1:3000; anti-TTLL1 pAb, 
1:5000; anti-CCP1 pAb, 1:2000). The membranes were incubated with HRP-labelled secondary antibodies 
(1:10000) and were developed with enhanced chemiluminescence reagent (ECL; GE Healthcare), and images 
were captured with a CCD camera (LAS-3000 mini; Fujifilm, Tokyo, Japan).
Immunocytochemistry. Immunocytochemistry was performed as previously described54. COS7 cells and 
IMCD3 cells were fixed with methanol at − 20 °C for 20 min or with 4% paraformaldehyde at 37 °C for 30 min. 
The fixed cells were blocked with 5% goat serum and 0.1% Triton X-100 in PBS at room temperature for 1 h, and 
then labelled with primary antibodies (DTE41, 1:200; M2, 1:5000; GT335, 1:2000; anti-Δ 2-tubulin pAb, 1:500; 
DM1A, 1:5000). The primary antibodies were labelled with the fluorescence-labelled secondary antibodies at 
4 μ g/mL. Zenon® antibody labelling kits (Thermo Fisher Scientific) were used when co-staining with primary 
antibodies derived from the same host. The fluorescence signals were observed with confocal laser scanning 
microscope (Fluoview FV1000, Olympus, Tokyo, Japan; SP8, Leica).
Immunohistochemistry. Mouse brain sections were blocked with 5% goat serum containing 0.1% Triton 
X-100 in PBS for 1 h at room temperature. The sections were incubated overnight at 4 °C with appropriate anti-
bodies (DTE41, 1:100; GT335, 1:2000; HM-2, 1:1000; anti-Δ 2-tubulin pAb, 1:1000; anti-MAP2 pAb, 1:1000; 
anti-calbindin pAb, 1:1000; DM1A, 1:2000). Primary antibodies were labelled with AlexaFluor-conjugated sec-
ondary antibodies at 50 μ g/mL for 1 h at room temperature. To confirm that mAb DTE41 binds specifically to the 
antigen of interest, the primary antibody was pre-incubated with antigen peptides at 10:1 molar ratio of antigen 
and antibody at 4 °C overnight. To guarantee that mAb DTE41 signals were bona fide, tissue sections were stained 
with secondary antibodies without adding the primary antibody. The fluorescent signals were observed using 
confocal laser scanning microscope (Fluoview FV1000, Olympus, SP8, Leica).
The sections of AD and non-AD samples were deparaffinised in xylene and rehydrated in a graded etha-
nol series. Heat-induced antigen retrieval was performed in sodium citrate buffer (pH 6.0) at 95 °C for 20 min. 
Endogenous peroxidase was inactivated by treating tissue sections with 3% H2O2/methanol for 15 min. The sec-
tions were blocked with 5% goat serum containing 0.1% Triton X-100 in PBS at room temperature for 1 h, and 
then labelled with primary antibodies (DTE41 at 1:100; GT335 at 1:2000; DM1A at 1:2000; anti-Δ 2 tubulin pAb 
at 1:500) at 4 °C overnight. The primary antibodies were labelled with HRP-conjugated secondary antibodies 
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(1:200, Vector Laboratories, Burlingame, CA) for 1 h at room temperature. The signal was visualised by using a 
DAB substrate kit (Vector Laboratories). Stained sections were dehydrated, and mounted with Harleco Synthetic 
Resin mounting medium (Sysmex, Kobe, Japan). Images were taken with Olympus BX51 microscope equipped 
with Olympus DP-72 camera.
Quantification and statistical analysis. ImageJ (http://rsb.info.nih.gov/ij/index.html) was used 
to quantify signal intensities. Band intensities of immunoblot were measured with a built-in command. 
Immunofluorescence signals were extracted as greyscale. Mean signals in the area without tissue sections were 
considered as background. The background signal was subtracted from the mean signal in the region of inter-
est (ROI). Photographs of DAB-stained slides were converted to 16-bit greyscale images. The darkness in the 
greyscale was measured as signals in the ROI. Statistical significances were evaluated with two-tailed Student’s 
t-test. A Pearson’s test was performed to analyse the correlations between immunochemical signals and Braak 
stages, disease duration, age at death, or post-mortem intervals. p < 0.05 was considered as statistically signifi-
cant. Quantified data were shown as mean ± standard error of mean (S.E.M), where the number of animals used, 
experiments done, or samples were provided as n or N.
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